Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2018
Price : $35 *
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Acronyms DOHA
- 31 Aug 2018 Biomarkers information updated
- 29 May 2018 Planned number of patients changed from 20 to 40.
- 29 May 2018 Status changed from not yet recruiting to recruiting.